These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37534525)

  • 1. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
    Gangat N; McCullough K; Abdelmagid M; Karrar O; Powell M; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Saliba A; Torghabeh MH; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Badar T; Foran J; Palmer J; Sproat L; Yi CA; Tefferi A
    Haematologica; 2024 Jan; 109(1):187-292. PubMed ID: 37534525
    [No Abstract]   [Full Text] [Related]  

  • 2. IDH1 inhibitor shows promising early results.
    Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

  • 6. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
    Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Gupta C; Kaulfuss S; Görlich K; Othman B; Chaturvedi A; Heuser M
    Ann Hematol; 2020 Jun; 99(6):1415-1417. PubMed ID: 32296913
    [No Abstract]   [Full Text] [Related]  

  • 8. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
    Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
    Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
    Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
    Molenaar RJ; Wilmink JW
    J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
    Lachowiez C; DiNardo CD; Stein E
    Cancer J; 2022 Jan-Feb 01; 28(1):21-28. PubMed ID: 35072370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of relapsed/refractory AML patients with IDH1
    Largeaud L; Bertoli S; Bérard E; Dufrechou S; Prade N; Gadaud N; Tavitian S; Bories P; Luquet I; Sarry A; Mas V; Huguet F; Delabesse E; Récher C
    Leuk Lymphoma; 2020 Feb; 61(2):473-476. PubMed ID: 31566052
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
    Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
    [No Abstract]   [Full Text] [Related]  

  • 16. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
    Benton CB; Ravandi F; Andreeff M; Kadia T; Ruvolo V; Qiu P; Wheeler DA; Garcia-Manero G; Cortes J; Kantarjian HM; Konopleva M
    Leuk Lymphoma; 2014 Jun; 55(6):1431-4. PubMed ID: 24033106
    [No Abstract]   [Full Text] [Related]  

  • 18. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.